Adalimumab Double Take: The Unexpected Return to Reference Humira

June 30, 2025

About 13% of patients who switch from Humira to an adalimumab biosimilar switch back to the originator, according to research from Truveta. However, the presented data may not tell the full story.

Expert Insights on Overcoming Patient Education Gaps, Biosimilar Financial Hurdles

June 29, 2025

The Top 5 Biosimilar Articles for the Week of June 23

June 27, 2025

Eye on Pharma: CHMP Aflibercept Decision; Omalizumab Results; Dupilumab Biosimilar Deal

June 26, 2025

Increasing Biosimilar Use Reflects Changing Practice in Pediatric IBD Care

June 25, 2025

The Top 5 Biosimilar Articles for the Week of June 24

June 28th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of June 24, 2024.

EHA 2024: Rituximab Biosimilars Improve Quality of Life, Infusion-Related Reactions

June 27th 2024

By Skylar Jeremias

Article

Two posters presented at the European Hematology Association’s annual meeting (EHA 2024) evaluated how rituximab biosimilars impact quality of life and infusion-related reactions in patients with lymphatic cancers.

Biosimilar Adoption in the UK: Patient and Consultant Views on Safety and Switching

June 26th 2024

By Skylar Jeremias

Article

Lack of knowledge and confidence in biosimilars continues despite growing education efforts, impacting provider willingness to prescribe biosimilar medicines and patient perceptions about their treatment and switching to a biosimilar.

Authors Spotlight Long-Term Solutions to Ensure Biosimilar Market Sustainability

June 25th 2024

By Skylar Jeremias

Article

Authors of a commentary piece propose solutions to sustainability issues for biosimilar markets and shed light on common sustainability challenges global markets face.

ASCO Posters Reflect on Reimbursement Trends, Combination Therapies Involving Biosimilars

June 24th 2024

By Skylar Jeremias

Article

Two posters from the American Society of Clinical Oncology (ASCO) annual meeting look at Medicare reimbursement trends for originator and biosimilar biologics, as well as a combination therapy utilizing a pegfilgrastim biosimilar in patients with advanced hepatocellular carcinoma.

IPD Analytics' Jeffrey Casberg Says IRA, PBM Legislation Reshape US Drug Costs

June 23rd 2024

By Cameron Santoro

Video

Jeffrey Casberg, RPh, MS, from IPD Analytics, explains why he believes policy changes and market forces are impacting the cost of drugs, including the Inflation Reduction Act (IRA) and pharmacy benefit manager (PBM) legislation.

No Differences in Treatment Persistence, Safety Detected for Anti-TNF Biosimilars vs Originators

June 22nd 2024

By Deana Ferreri, PhD

Article

A real-world study using data from the French National Health Data System, found no significant differences in treatment persistence or safety between anti-tumor necrosis factor (TNF)-α biosimilars and reference products in all indications of these biologics.

The Top 5 Biosimilar Articles for the Week of June 17

June 21st 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of June 17, 2024.

FDA Draft Guidance Removes Switching Study Requirements for Biosimilar Interchangeability

June 20th 2024

By Skylar Jeremias

Article

The FDA has issued an update to its guidance on requiring switching study data for biosimilars to be granted interchangeability, citing new science that shows these studies aren’t needed to establish biosimilar safety.

Overcoming Economic, Noneconomic Barriers to Biosimilar Adoption in Oncology

June 20th 2024

By Skylar Jeremias

Article

The broader adoption of biosimilar drugs has the potential to significantly reduce cancer care costs and improve patient access to more affordable treatments, benefiting both patients and payers. However, a recent review highlights that biosimilar uptake has been hindered by various economic, practical, attitudinal, and psychological factors.